These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 34661180)

  • 1. Immunogenicity of a BNT162b2 vaccine booster in health-care workers.
    Saiag E; Goldshmidt H; Sprecher E; Ben-Ami R; Bomze D
    Lancet Microbe; 2021 Dec; 2(12):e650. PubMed ID: 34661180
    [No Abstract]   [Full Text] [Related]  

  • 2. [Humoral immunity against SARS-CoV-2 in workers of social health care centers of Castilla y León after vaccination with the BNT162b2 mRNA vaccine from Pfizer/Biontech.].
    Casas Fischer R
    Rev Esp Salud Publica; 2021 Oct; 95():. PubMed ID: 34690347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in Patients Undergoing Hemodialysis.
    Yau K; Abe KT; Naimark D; Oliver MJ; Perl J; Leis JA; Bolotin S; Tran V; Mullin SI; Shadowitz E; Gonzalez A; Sukovic T; Garnham-Takaoka J; de Launay KQ; Takaoka A; Straus SE; McGeer AJ; Chan CT; Colwill K; Gingras AC; Hladunewich MA
    JAMA Netw Open; 2021 Sep; 4(9):e2123622. PubMed ID: 34473256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of BNT162b2 vaccine against the B.1.1.7 variant of SARS-CoV-2 among healthcare workers in Brescia, Italy.
    Sansone E; Tiraboschi M; Sala E; Albini E; Lombardo M; Castelli F; De Palma G
    J Infect; 2021 Jul; 83(1):e17-e18. PubMed ID: 33965428
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparison of mRNA-1273 and BNT162b2 SARS-CoV-2 mRNA Vaccine Immunogenicity in Kidney Transplant Recipients.
    Haller MC; Kaiser RA; Langthaler S; Brandstetter C; Apfalter P; Kerschner H; Cejka D
    Transpl Int; 2021; 35():10026. PubMed ID: 35185359
    [No Abstract]   [Full Text] [Related]  

  • 6. Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers.
    Angel Y; Spitzer A; Henig O; Saiag E; Sprecher E; Padova H; Ben-Ami R
    JAMA; 2021 Jun; 325(24):2457-2465. PubMed ID: 33956048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Anti-SARS-CoV-2 S1 Receptor-Binding Domain Antibody Immunoassays in Health Care Workers Before and After the BNT162b2 mRNA Vaccine.
    Carta M; Marinello I; Cappelletti A; Rodolfi A; Cerrito E; Bernasconi C; Gottardo M; Dal Lago F; Rizzetto D; Barzon E; Giavarina D
    Am J Clin Pathol; 2022 Feb; 157(2):212-218. PubMed ID: 34463321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines.
    Montoya JG; Adams AE; Bonetti V; Deng S; Link NA; Pertsch S; Olson K; Li M; Dillon EC; Frosch DL
    Microbiol Spectr; 2021 Dec; 9(3):e0116221. PubMed ID: 34756093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BNT162b2 Vaccine Booster and Covid-19 Mortality.
    Pilz S
    N Engl J Med; 2022 Mar; 386(10):1000. PubMed ID: 35139267
    [No Abstract]   [Full Text] [Related]  

  • 10. BNT162b2 Vaccine Booster and Covid-19 Mortality.
    Rohban T
    N Engl J Med; 2022 Mar; 386(10):1000. PubMed ID: 35139266
    [No Abstract]   [Full Text] [Related]  

  • 11. Persistence of Immune Response in Health Care Workers After Two Doses BNT162b2 in a Longitudinal Observational Study.
    Herzberg J; Fischer B; Lindenkamp C; Becher H; Becker AK; Honarpisheh H; Guraya SY; Strate T; Knabbe C
    Front Immunol; 2022; 13():839922. PubMed ID: 35309303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Humoral immune response after different SARS-CoV-2 vaccination regimens.
    Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
    BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BNT162b2 Vaccine Booster and Covid-19 Mortality. Reply.
    Arbel R; Sergienko R; Hammerman A
    N Engl J Med; 2022 Mar; 386(10):1000-1001. PubMed ID: 35139268
    [No Abstract]   [Full Text] [Related]  

  • 14. Humoral and Cellular Immunogenicity of the BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine in Nursing Home Residents.
    Van Praet JT; Vandecasteele S; De Roo A; De Vriese AS; Reynders M
    Clin Infect Dis; 2021 Dec; 73(11):2145-2147. PubMed ID: 33825869
    [No Abstract]   [Full Text] [Related]  

  • 15. The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients.
    Zitt E; Davidovic T; Schimpf J; Abbassi-Nik A; Mutschlechner B; Ulmer H; Benda MA; Sprenger-Mähr H; Winder T; Lhotta K
    Front Immunol; 2021; 12():704773. PubMed ID: 34220867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamics of Antibody Response to BNT162b2 mRNA COVID-19 Vaccine: A 7-Month Follow-Up Study.
    Olariu TR; Ursoniu S; Marincu I; Lupu MA
    Medicina (Kaunas); 2021 Dec; 57(12):. PubMed ID: 34946275
    [No Abstract]   [Full Text] [Related]  

  • 17. Impact of prior infection status on antibody response to the BNT162b2 mRNA COVID-19 vaccine in healthcare workers at a COVID-19 referral hospital in Milan, Italy.
    Milazzo L; Pezzati L; Oreni L; Kullmann C; Lai A; Gabrieli A; Bestetti G; Beschi C; Conti F; Ottomano C; Gervasoni C; Meroni L; Galli M; Antinori S; Ridolfo AL
    Hum Vaccin Immunother; 2021 Dec; 17(12):4747-4754. PubMed ID: 35086438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BNT162b2 mRNA COVID-19 Vaccine: First Approval.
    Lamb YN
    Drugs; 2021 Mar; 81(4):495-501. PubMed ID: 33683637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Editorial Comment from Dr Kobayashi to Effect of active anticancer therapy on serologic response to SARS-CoV-2 BNT162b2 vaccine in patients with urothelial and renal cell carcinoma.
    Kobayashi T
    Int J Urol; 2022 Jul; 29(7):739. PubMed ID: 35478200
    [No Abstract]   [Full Text] [Related]  

  • 20. Evaluation of the QuantiFERON SARS-CoV-2 assay to assess cellular immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in individuals with low and high humoral response.
    Tychala A; Meletis G; Katsimpourlia E; Gkeka I; Dimitriadou R; Sidiropoulou E; Skoura L
    Hum Vaccin Immunother; 2021 Dec; 17(12):5148-5149. PubMed ID: 34714711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.